EGFR and non-small cell lung carcinoma: Through strict entry and exclusion criteria, 148 advanced/metastatic NSCLC patients with wild-type or unknown EGFR status were enrolled in our study, and randomly assigned to CON group (n=50) or DOX group (n=48) or SCA group (n=50) until disease progression or the development of intolerable adverse events.